Marker Therapeutics (FRA:GX1) Institutional Ownership: 4.26% (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GX1 Marker Therapeutics Inc FRA:GX1
32 GF Score
Price €0.84
! 1 Warning Sign
View Full Analysis

What is Marker Therapeutics Institutional Ownership?

Marker Therapeutics FRA:GX1 -1.75% 32 Institutional Ownership is 4.26% as of Aug. 19, 2026. GuruFocus rates FRA:GX1 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Marker Therapeutics's institutional ownership is 4.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Marker Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Marker Therapeutics's Float Percentage Of Total Shares Outstanding is 80.96%.

Marker Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Marker Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics Institutional Ownership Chart

Marker Therapeutics Historical Data

The historical data trend for Marker Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 4.90 4.88 4.62 2.94 3.42 3.50 4.09 4.21 4.19 4.26
FRA:GX1
32GF Score
Marker Therapeutics Inc FRA:GX1
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marker Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 4.26% mean?
Marker Therapeutics (FRA:GX1) has a Institutional Ownership of 4.26% as of Aug. 19, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Marker Therapeutics and its competitors.
Is Marker Therapeutics' Institutional Ownership too high?
Marker Therapeutics' current Institutional Ownership is 4.26%. Overall, Marker Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' Institutional Ownership compare to NCEL and HOWL?
Marker Therapeutics' Institutional Ownership of 4.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Marker Therapeutics and its competitors. Marker Therapeutics's current Institutional Ownership is 4.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (FRA:GX1) has a current Institutional Ownership of 4.26%. The current Institutional Ownership is 4.26%. Marker Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Marker Therapeutics (FRA:GX1), the current Institutional Ownership is 4.26% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marker Therapeutics Business Description

Other Exchanges MRKR:USA
Address 2450 Holcombe Boulevard, TMC Partners Office 1.311, Houston, TX, USA, 77021
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
32GF Score

Get the complete analysis for FRA:GX1

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.84
Price